Opaleye Management Inc. bought $125k of ETON
owner at Eton Pharmaceuticals, Inc.. 7,930 shares at an average of $15.82, traded Jun 10, 2025, filed Jun 12, 2025.
Score components
- +12Role10% owner
- +11Trade size$125k at market
- -5Relative to holdingsUnder 1% of holdings (0.3%)
- +4Price context22% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- +10Track recordMedian 6-month excess return +95% over 3 past buys
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.1%, 3m +21.1%, 6m +16.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001641172-25-014868, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 10, 2025 | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | +5,000 | $15.82 | $79k | 2,770,000 | Jun 12, 2025 |
| Jun 10, 2025 | POpen-market purchase Common Stock, par value $0.001 per shareindirect: Managed Account | +2,930 | $15.82 | $46k | 85,000 | Jun 12, 2025 |
Related signals
Other insiders at Eton Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ETONsell Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $229k 4,166 shares | -9% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $1.6M 25,000 shares | -40% | |
| 65Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $6.1M 100,000 shares | -9% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $4.8M 126,685 shares | -5% | |
| 45Moderate | ETONsell Eton Pharmaceuticals, Inc. | Jennifer McKie Adams director | $1.6M 50,000 shares | -100% | |
| 63Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $3.8M 120,000 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.